



(51) International Patent Classification:

C12N 5/074 (2010.01) C12N 5/0781 (2010.01)
C12N 15/85 (2006.01) C07K 14/52 (2006.01)
C12N 5/0789 (2010.01) C07K 14/705 (2006.01)
C12N 5/0783 (2010.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2022/073396

(22) International Filing Date:

01 July 2022 (01.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/218,204 02 July 2021 (02.07.2021) US
63/265,190 09 December 2021 (09.12.2021) US
63/341,943 13 May 2022 (13.05.2022) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) Inventors: **VALAMEHR, Bahram**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **BJORDAHL, Ryan**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **GOODRIDGE, Jode**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **WILLIAMS, Alan**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **MBO-FUNG, Rina**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(74) Agent: **GIERING, Jeffery, C. et al.**; Greenberg Traurig, LLP, 18565 Jamboree Road, Suite 500, Irvine, CA 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES




FIG. 16

(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Embodiments of derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*